Tetraphase Pharmaceuticals is developing a portfolio of next generation antibiotics based on a dynamic drug engine that enables the design of novel antibiotics with drug properties to address unmet needs for serious infections.

Tetraphase’s breakthrough synthetic chemistry platform enables – for the first time – the ability to overcome the technical challenges of modifying core tetracycline scaffolds so that this important class of antibiotics can be evolved and reinvigorated to create powerful new antibiotics capable of treating serious infections, including Gram-negative and multi-drug resistant strains.

Tetraphase is rapidly advancing a clinical pipeline of potent novel antibiotics that include intravenous and oral drug candidates with the potential to treat a diverse range of infections, including broad-spectrum and selective-spectrum infections. Tetraphase’s proprietary synthetic chemistry platform has the potential to design unique drug structures for expansive therapeutic opportunities.